⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer

Official Title: Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study

Study ID: NCT02619435

Interventions

regorafenib

Study Description

Brief Summary: The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

AO G. Rummo, Benevento, , Italy

Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, , Italy

Seconda Università di Napoli, Napoli, , Italy

AO S. Carlo, Potenza, , Italy

Contact Details

Name: Antonio Avallone, M.D.

Affiliation: National Cancer Institute, Naples

Role: PRINCIPAL_INVESTIGATOR

Name: Alfredo Budillon, M.D.

Affiliation: National Cancer Institute, Naples

Role: PRINCIPAL_INVESTIGATOR

Name: Francesco Perrone, M.D.

Affiliation: National Cancer Institute, Naples

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: